Skip to main content

Table 2 Prevalence of comorbidities

From: Chronic constipation diagnosis and treatment evaluation: the “CHRO.CO.DI.T.E.” study

 

IBS-C: 275

FC: 549

NRC: 54

p-value1

Dyspepsia

128 (46.5%)

200 (36.4%)

14 (25.9%)#

<0.005

Depression/anxiety

111 (40.4%)

164 (29.9%)*

9 (16.7%)**

<0.0005

GERD

98 (35.6%)

167 (30.4%)

8 (14.8%)## ###

<0.01

Sleep disturbances

87 (31.6%)

141 (25.7%)

13 (24.1%)

ns

Hypertension

45 (16.4%)

135 (24.6%)§

11 (20.4%)

<0.05

Urinary disturbances

52 (18.9%)

115 (20.9%)

8 (14.8%)

ns

Thyroid disease

26 (9.4%)

65 (11.8%)

6 (11.1%)

ns

Vaginitis

29 (10.5%)

46 (8.4%)

4 (7.4%)

ns

Dyspareunia

30 (10.9%)

38 (6.9%)

4 (7.4%)

ns

Diabetes

7 (2.5%)

29 (5.3%)

3 (5.6%)

ns

Fibromyalgia

16 (5.8%)

18 (3.3%)

-

ns

Other

36 (13.1)

56 (10.2%)

7 (13%)

ns

  1. IBS-C irritable bowel syndrome with constipation, FC functional constipation, NRC patients do not accomplish Rome III criteria, GERD gastroesophageal reflux disease
  2. 1 p values are referred to the differences between IBS-C, FC and NRC groups, in particular
  3. *p < 0.01 vs IBS-C; **p < 0.005 vs IBS-C; #p < 0.05 vs IBS-C and FC; ##p < 0.01 vs IBS-C
  4. ###p < 0.05 vs FC; §p < 0.05 vs IBS-C; ns: not statistically significant